Treatment of pseudobulbar affect in ALS: October 26 highlight and commentary.
Hingorani
Vijay N
VN
Kittrelle
Jeffrey P
JP
D000690:Amyotrophic Lateral Sclerosis / Q000150:complications*; D000996:Antitussive Agents / Q000378:metabolism / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000592:standards; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism; D003915:Dextromethorphan / Q000378:metabolism / Q000627:therapeutic use*; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005820:Genetic Testing / Q000592:standards; D005838:Genotype; D006801:Humans; D020828:Pseudobulbar Palsy / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011802:Quinidine / Q000627:therapeutic use*
D000996:Antitussive Agents; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D065607:Cytochrome P-450 Enzyme Inhibitors; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D003915:Dextromethorphan; D003577:Cytochrome P-450 Enzyme System; D019389:Cytochrome P-450 CYP2D6; D011802:Quinidine